Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2016-12-15 Director's Dealing
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Director's Dealing 2016
Director's Dealing Classification · 100% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and explicitly references Article 19 of Regulation No. 596/2014 concerning market abuse. It details transactions (specifically the granting of Restricted Stock Units/share options) involving securities of the company (Genmab A/S) by persons discharging managerial responsibilities (directors/senior management) and persons closely associated with them. This structure perfectly matches the definition of Director's Dealing reports, which track insider transactions.
2016-12-15 English
Director's Dealing 2016
Director's Dealing Classification · 100% confidence The document text explicitly references 'Article 19 of Regulation No. 596/2014 on Market Abuse' and details transactions (Grant of Restricted Stock Units) made by individuals discharging managerial responsibilities (Chairman and Members of the Board of Directors) in the company's shares. This structure and content are characteristic of mandatory insider trading disclosures, specifically reporting personal share transactions by directors and executives. This aligns directly with the definition for Director's Dealing (DIRS).
2016-12-15 Danish
Tildeling af restricted stock units til bestyrelsesmedlemmer, direktion og medarbejdere og tildeling af warrants til direktion og medarbejdere i Genmab
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement regarding the grant of restricted stock units (RSUs) and warrants to board members, management, and employees. This type of disclosure relates to incentive-based remuneration and capital structure changes involving equity-based compensation. While it involves directors and management, it is a corporate announcement of a grant program rather than a report of individual insider trades (DIRS). It fits best under 'Share Issue/Capital Change' (SHA) as it details the issuance of rights to shares, or alternatively 'Regulatory Filings' (RNS). Given the specific nature of equity grants, SHA is the most precise category.
2016-12-15 English
Tildeling af restricted stock units til bestyrelsesmedlemmer, direktion og medarbejdere og tildeling af warrants til direktion og medarbejdere i Genmab
Share Issue/Capital Change Classification · 95% confidence The document is a corporate announcement from Genmab regarding the allocation of restricted stock units (RSUs) and warrants to board members, management, and employees. This type of disclosure relates to share-based incentive programs and capital changes (issuance of rights to shares). While it involves directors and employees, it is a broad corporate announcement of a share-based incentive program rather than a specific individual 'Director's Dealing' (DIRS) report. It fits best under 'Share Issue/Capital Change' (SHA) as it details the creation and allocation of new equity-linked instruments.
2016-12-15 English
Share Issue/Capital Change 2016
Share Issue/Capital Change Classification · 99% confidence The document is titled "Company Announcement" and details the decision by the board to grant restricted stock units (RSUs) and warrants to employees and management. This action directly relates to the company's compensation structure and the issuance of equity instruments (shares/options) to personnel. This falls under the category of changes related to capital structure or employee incentive plans. While it involves shares, the primary focus is the granting of stock-based compensation, which is often linked to remuneration or capital changes. However, the specific action described—granting stock units and warrants—is a form of capital change/share issuance related to employee compensation. Reviewing the definitions, 'SHA' (Share Issue/Capital Change) is a possibility, but 'DEF 14A' (Remuneration Information) is also relevant as it concerns executive/director compensation plans. Since this is a direct announcement of the grant of equity awards (RSUs and Warrants) rather than a full report on executive pay (like a DEF 14A), and it involves the issuance of potential shares, 'SHA' (Share Issue/Capital Change) is a strong fit, as is 'CAP' (Capital/Financing Update). Given the context of granting stock options/RSUs, which directly impacts the share count and capital structure, 'SHA' is the most precise fit among the options for the actual transaction described, although 'DEF 14A' covers the underlying remuneration policy. Since this is a specific transaction announcement about equity awards, I will classify it as a Share Issue/Capital Change (SHA).
2016-12-15 English
Share Issue/Capital Change 2016
Share Issue/Capital Change Classification · 99% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and dated December 15, 2016. The content explicitly details the decision by the board to grant restricted stock units (RSUs) and warrants to employees and management. This action directly relates to the company's compensation structure and the issuance of equity instruments to personnel. This falls under the category of changes related to capital structure or employee equity plans. While it involves shares, it is a specific announcement about granting options/RSUs rather than a general share repurchase (POS) or a broad capital change (SHA). However, the core subject is the granting of stock-based compensation, which is often linked to remuneration or capital structure. Given the options, the closest fit for an announcement detailing the granting of stock options and warrants to employees is related to capital/financing activities or insider transactions, but since it's an announcement about granting equity incentives, it is most closely related to 'Share Issue/Capital Change' (SHA) or potentially 'Remuneration Information' (DEF 14A) if it were a proxy filing. Since this is a direct announcement of the grant, and it involves the issuance of potential new shares via options/warrants, 'SHA' (Share Issue/Capital Change) is plausible, but 'POS' (Transaction in Own Shares) is usually for buybacks/sales. Since this is a specific grant announcement, and not a general regulatory filing fallback, I will check the definitions again. The document describes the granting of RSUs and Warrants, which are forms of equity compensation. This is a specific corporate action. If it were a general regulatory filing that didn't fit, it would be RNS. Since it details the mechanics of stock options/warrants being granted, it is a specific corporate action announcement. Given the available codes, 'SHA' (Share Issue/Capital Change) covers changes to the capital structure, which includes the issuance of options/warrants that lead to future share issuance. Alternatively, if this were a US filing, it might be part of a DEF 14A (Remuneration). Since this is a Danish company announcement, and it details the grant of equity instruments, 'SHA' is the most appropriate fit among the provided options for an action affecting the share pool, although 'RNS' (Regulatory Filings) is a strong secondary candidate for non-US specific announcements. Given the specific nature of granting equity awards, I will classify it as 'SHA' as it directly impacts the potential share count/capital structure, or 'RNS' as a general regulatory announcement. Since it is a specific corporate action announcement, and not a general filing announcement (RPA), I lean towards the specific action. However, looking at the definitions, none perfectly capture 'Stock Option Grant Announcement'. Since it is a formal announcement ('Selskabsmeddelelse') detailing the grant of equity instruments, and it is not a standard financial report, 'RNS' (Regulatory Filings - fallback) is often used for such specific, non-standard announcements in a mixed set of definitions. Let's re-evaluate: It is an announcement about granting stock options/warrants. This is a form of compensation disclosure, but also a capital structure event. Given the high specificity of the other codes, and the lack of a dedicated 'Stock Option Grant' code, 'RNS' (General regulatory announcement) is the safest fallback for a specific corporate action announcement that doesn't fit the financial report types (10-K, IR, ER) or specific transaction types (DIV, POS). I will use RNS as the most appropriate general regulatory announcement code for this specific Danish company announcement regarding equity grants.
2016-12-15 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.